Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Silence Therapeutics plc focuses on developing RNA interference (RNAi) therapeutics for serious diseases, leveraging its proprietary mRNA technology platform. The company operates primarily in the United Kingdom and has strategic partnerships with major pharmaceutical companies to advance its pipeline, which includes candidates targeting liver diseases and cancer.
Silence Therapeutics generates revenue through strategic partnerships and collaborations with larger pharmaceutical companies, providing access to its proprietary RNAi technology. The company has no current product sales, relying on upfront payments, milestone payments, and royalties from its partners.
Progress in clinical trials for RNAi therapeutics, particularly for liver diseases
Partnership announcements or updates with major pharmaceutical companies
Regulatory approvals for pipeline candidates
Changes in investor sentiment towards biotech sector
Regulatory changes impacting drug approval processes
Technological disruption in RNAi and gene therapy fields
Emerging RNAi therapies from competitors
Potential for larger pharmaceutical companies to develop in-house capabilities
High cash burn rate with negative operating cash flow
Dependence on external funding for R&D
low - As a biotechnology firm focused on innovative therapies, Silence Therapeutics is less sensitive to economic cycles, but overall healthcare spending trends can influence funding.
Interest rates affect the cost of capital for R&D funding. Higher rates could increase financing costs, potentially impacting the company's ability to fund its development pipeline.
minimal - The company has no debt on its balance sheet, reducing credit risk.
growth - Investors looking for high-risk, high-reward opportunities in biotechnology.
high - The stock has exhibited significant price volatility due to its developmental stage and reliance on clinical trial outcomes.
